Health Care & Life Sciences » Biotechnology | Selecta Biosciences Inc.

Selecta Biosciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
17,836.00
36,595.00
84,219.00
96,638.00
37,403
Total Accounts Receivable
674.00
824.00
215.00
63.00
-
Other Current Assets
602.00
1,494.00
2,382.00
1,979.00
4,673
Total Current Assets
19,112.00
38,913.00
86,816.00
98,680.00
42,076
Net Property, Plant & Equipment
1,983.00
2,029.00
2,047.00
2,091.00
2,127
Other Assets
1,133.00
1,882.00
438.00
329.00
-
Total Assets
22,228.00
42,824.00
89,301.00
101,100.00
44,482
ST Debt & Current Portion LT Debt
2,578.00
-
4,067.00
-
Accounts Payable
351.00
2,179.00
3,882.00
1,606.00
Other Current Liabilities
6,302.00
5,111.00
5,757.00
9,367.00
Total Current Liabilities
9,231.00
7,290.00
13,706.00
10,973.00
Long-Term Debt
4,824.00
11,855.00
7,977.00
21,042.00
Other Liabilities
1,895.00
2,690.00
12,661.00
17,271.00
Total Liabilities
15,950.00
21,835.00
34,344.00
49,286.00
Common Equity (Total)
87,755.00
116,493.00
54,957.00
51,814.00
Total Shareholders' Equity
6,278.00
20,989.00
54,957.00
51,814.00
Total Equity
6,278.00
20,989.00
54,957.00
51,814.00
Liabilities & Shareholders' Equity
22,228.00
42,824.00
89,301.00
101,100.00
Preferred Stock (Carrying Value)
94,033.00
137,482.00
-
-

About Selecta Biosciences

View Profile
Address
480 Arsenal Way
Watertown Massachusetts 02472
United States
Employees -
Website http://www.selectabio.com
Updated 07/08/2019
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. Its proprietary pipeline includes SVP-enabled enzyme, oncology, and gene therapies.